Company: GIFLF
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001104659-25-071915
Chunk: 4

Company: Grifols SA
Filing Date: 2025-07-30
Form: 6-K
Chunk 4
---
 dollar
presents a headwind to reported Revenue and EBITDA in the second half, the impact on Group Profit, leverage and Free Cash Flow pre-M&A
is expected to be broadly neutral. The Group expects to largely mitigate this headwind through a combination of the benefit of underlying
business momentum and targeted cost levers.

Alternative Performance Measures (APMs)

This document contains the following Alternative
Performance Measures (APMs): Consolidated EBITDA Reported, Consolidated EBITDA Adjusted, Leverage Ratio as per the Credit Facility, Net
Debt as per the Credit Facility, Free Cash Flow, Working Capital, and non-recurring items. For further details on the definition, explanation
on the use, and reconciliation of APMs, please see the Appendix of the Presentation as well as the “Alternative Performance Measures”
document from Grifols website .

Page 3 of 5

CONFERENCE CALL

Grifols will host a conference call today, July 29,
2025, at 6:30pm CET/12:30pm EST to provide review of the company’s business results for the second quarter of 2025. To view and
listen to the webcast and view the presentation, click on or visit the website .
Participants are advised to register in advance of the conference call.

Media:

Grifols Press Office

+34 93 571 00
02

Investors:

Investor Relations & Sustainability

+34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded
in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived
medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more
than 110 countries.

Patient needs and Grifols’
ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s
innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across
four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues
to grow its network of donation centers, the world’s largest with close to 400 across North America, Europe, Africa and the Middle
East, and China.

As a recognized leader in transfusion
medicine, Grif